Publications

Patient-Reported Outcomes (Pros) from Destiny-Breast04, a Randomized Phase Iii Study of Trastuzumab Deruxtecan (T-Dxd) Vs Treatment of Physician's Choice (Tpc) in Patients (Pts) with Her2-Low Metastatic Breast Cancer (Mbc)

AuthID
P-00X-M28

Author(s)

Ueno, NT

Jacot, W

Yamashita, T

Sohn, J

Tokunaga, E

Prat, A

Tsurutani, J

Park, YH

Rugo, HS

Xu, B

Cardoso, F

Mitri, Z

Mahtani, R

Dunton, K

Wang, Y

Gambhire, D

Cottone, F

Harbeck, N

Cameron, DA

Modi, S

Document Type

Abstract

Year published

2022

Published

in ANNALS OF ONCOLOGY, ISSN: 0923-7534

Volume: 33, Issue: 7, Pages: S632-S633 (2)

Conference

Annual Meeting of the European-Society-For-Medical-Oncology (Esmo), Date: SEP 09-13, 2022, Location: ELECTR NETWORK, Sponsors: European Soc Med Oncol

Indexing

Wos^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1016/j.annonc.2022.07.256

Wos: WOS:000866211600206

Source Identifiers

ISSN: 0923-7534

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Patient-Reported Outcomes (Pros) from Destiny-Breast04, a Randomized Phase Iii Study of Trastuzumab Deruxtecan (T-Dxd) Vs Treatment of Physician's Choice (Tpc) in Patients (Pts) with Her2-Low Metastatic Breast Cancer (Mbc)

Useful Links

Get Help

Federated Authentication (Click on the image)

Patient-Reported Outcomes (Pros) from Destiny-Breast04, a Randomized Phase Iii Study of Trastuzumab Deruxtecan (T-Dxd) Vs Treatment of Physician's Choice (Tpc) in Patients (Pts) with Her2-Low Metastatic Breast Cancer (Mbc)

Useful Links

Get Help